Stay updated on NIMBLe Study: Clinical Trial_hyperMutated Cancers
Sign up to get notified when there's something new on the NIMBLe Study: Clinical Trial_hyperMutated Cancers page.

Latest updates to the NIMBLe Study: Clinical Trial_hyperMutated Cancers page
- Check2 days agoChange DetectedRevision: v3.4.2 was added; the prior v3.4.1 notice was removed. These changes are limited to system-level updates and do not affect study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check9 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and NIH operations. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check16 days agoChange DetectedAdded a glossary toggle and new metadata labels, including 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', along with a new revision tag 'v3.4.0'. The previous label variants 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data' and the older revision 'v3.3.4' were removed.SummaryDifference0.2%

- Check30 days agoChange DetectedFooter revision updated from v3.3.3 to v3.3.4. No substantive changes to study details, locations, or eligibility are visible in the screenshots.SummaryDifference0.1%

- Check51 days agoChange DetectedLocations section added listing New York, Alberta, British Columbia, and Ontario; HHS Vulnerability Disclosure removed; location headings consolidated under a single Locations section (Revision: v3.3.3).SummaryDifference0.5%

- Check73 days agoChange DetectedThe page revision was updated from v3.3.1 to v3.3.2, with no substantive changes to the study details or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to NIMBLe Study: Clinical Trial_hyperMutated Cancers
Enter your email address, and we'll notify you when there's something new on the NIMBLe Study: Clinical Trial_hyperMutated Cancers page.